The gut microbiota in inflammatory bowel disease
P Qiu, T Ishimoto, L Fu, J Zhang, Z Zhang… - Frontiers in cellular and …, 2022 - frontiersin.org
Epidemiological surveys indicate that the incidence of inflammatory bowel disease (IBD) is
increasing rapidly with the continuous growth of the economy. A large number of studies …
increasing rapidly with the continuous growth of the economy. A large number of studies …
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind …
S Danese, S Vermeire, W Zhou, AL Pangan… - The lancet, 2022 - thelancet.com
Background There is a great unmet need for advanced therapies that provide rapid, robust,
and sustained disease control for patients with ulcerative colitis. We assessed the efficacy …
and sustained disease control for patients with ulcerative colitis. We assessed the efficacy …
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
WJ Sandborn, S Vermeire, L Peyrin-Biroulet… - The Lancet, 2023 - thelancet.com
Background Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor
modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable …
modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable …
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
JS Lasa, PA Olivera, S Danese… - The Lancet …, 2022 - thelancet.com
Background There is a growing armamentarium for the treatment of moderate-to-severe
ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small …
ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small …
Newer biologic and small-molecule therapies for inflammatory bowel disease
DC Baumgart, C Le Berre - New England Journal of Medicine, 2021 - Mass Medical Soc
Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …
bowel disease. This review covers newer treatments that reflect our understanding of the …
A comprehensive overview of globally approved JAK inhibitors
Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
Inhibition of Janus kinase (JAK) family enzymes is a popular strategy for treating
inflammatory and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors …
inflammatory and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors …
Disease-modifying anti-asthmatic drugs
M Lommatzsch, GG Brusselle, GW Canonica… - The Lancet, 2022 - thelancet.com
Drugs available for asthma treatment in the first decades of the 20th century
(sympathomimetic agents such as oral ephedrine, intravenous adrenaline, or inhaled …
(sympathomimetic agents such as oral ephedrine, intravenous adrenaline, or inhaled …
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis
Objective Biological therapies and small molecules continue to be evaluated in moderate to
severely active ulcerative colitis, but are often studied in placebo-controlled trials, meaning …
severely active ulcerative colitis, but are often studied in placebo-controlled trials, meaning …